Objectives: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial. Methods: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpoint was change from baseline (CFB) at end of study (EOS) in the ADHD Rating Scale-5 (ADHD-RS-5) Total score. Statistical analyses included sequential testing for multiple treatment comparisons. Key secondary endpoints included: Clinical Global Impression-Improvement (CGI-I) score at EOS and CFB at EOS in the Conners 3-Parent Short Form (Conners 3-PS) Composite T-score and Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) Total average score. Results: The CFB at EOS ADHD-RS-5 Total score (least square [LS] means ± SE) for 400-mg/day, 600-mg/day SPN-812, and placebo was -18.3 ± 1.36, -16.7 ± 1.39, and -13.2 ± 1.38, respectively. The difference vs. placebo was statistically significant only for the 400-mg/day SPN-812 treatment group (600 mg/day: p = 0.0712; 400 mg/day: p = 0.0082). Neither dose could be considered superior to placebo due to the use of statistical method of sequential testing. Significant improvements were observed on a number of secondary endpoints. SPN-812 was well tolerated at both doses, with <5% discontinuation rate due to adverse events. Conclusions: Treatment with 400- but not 600-mg/day SPN-812 resulted in statistically significant improvement in the primary endpoint. The negative result seen in the 600-mg/day SPN-812 group was likely due to an unusually high placebo response. Safety data were consistent across all doses in the SPN-812 trials.
Objectives: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial. Methods: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpoint was change from baseline (CFB) at end of study (EOS) in the ADHD Rating Scale-5 (ADHD-RS-5) Total score. Statistical analyses included sequential testing for multiple treatment comparisons. Key secondary endpoints included: Clinical Global Impression-Improvement (CGI-I) score at EOS and CFB at EOS in the Conners 3-Parent Short Form (Conners 3-PS) Composite T-score and Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) Total average score. Results: The CFB at EOS ADHD-RS-5 Total score (least square [LS] means ± SE) for 400-mg/day, 600-mg/day SPN-812, and placebo was -18.3 ± 1.36, -16.7 ± 1.39, and -13.2 ± 1.38, respectively. The difference vs. placebo was statistically significant only for the 400-mg/day SPN-812 treatment group (600 mg/day: p = 0.0712; 400 mg/day: p = 0.0082). Neither dose could be considered superior to placebo due to the use of statistical method of sequential testing. Significant improvements were observed on a number of secondary endpoints. SPN-812 was well tolerated at both doses, with <5% discontinuation rate due to adverse events. Conclusions: Treatment with 400- but not 600-mg/day SPN-812 resulted in statistically significant improvement in the primary endpoint. The negative result seen in the 600-mg/day SPN-812 group was likely due to an unusually high placebo response. Safety data were consistent across all doses in the SPN-812 trials.
Authors: David V Sheehan; Kathy H Sheehan; R Douglas Shytle; Juris Janavs; Yvonne Bannon; Jamison E Rogers; Karen M Milo; Saundra L Stock; Berney Wilkinson Journal: J Clin Psychiatry Date: 2010-03 Impact factor: 4.384
Authors: Azmi Nasser; Tesfaye Liranso; Toyin Adewole; Nicholas Fry; Joseph T Hull; Fatima Chowdhry; Gregory D Busse; Andrew J Cutler; Nandita Joshi Jones; Robert L Findling; Stefan Schwabe Journal: Clin Ther Date: 2020-07-25 Impact factor: 3.393
Authors: Kelly Posner; Gregory K Brown; Barbara Stanley; David A Brent; Kseniya V Yershova; Maria A Oquendo; Glenn W Currier; Glenn A Melvin; Laurence Greenhill; Sa Shen; J John Mann Journal: Am J Psychiatry Date: 2011-12 Impact factor: 18.112
Authors: Joseph Biederman; Michael C Monuteaux; Eric Mick; Thomas Spencer; Timothy E Wilens; Julie M Silva; Lindsey E Snyder; Stephen V Faraone Journal: Psychol Med Date: 2006-02 Impact factor: 7.723
Authors: Alonso Montoya; Amaia Hervas; Esther Cardo; Josep Artigas; María J Mardomingo; José A Alda; Xavier Gastaminza; María J García-Polavieja; Inmaculada Gilaberte; Rodrigo Escobar Journal: Curr Med Res Opin Date: 2009-11 Impact factor: 2.580
Authors: Stephen V Faraone; Russell J Schachar; Russell A Barkley; Rick Nullmeier; F Randy Sallee Journal: J Child Adolesc Psychopharmacol Date: 2017-04-10 Impact factor: 2.576
Authors: Hannah W Haddad; Paul B Hankey; Jimin Ko; Zahaan Eswani; Pravjit Bhatti; Amber N Edinoff; Adam M Kaye; Alan D Kaye Journal: Health Psychol Res Date: 2022-07-28
Authors: Christopher L Robinson; Katelyn Parker; Saurabh Kataria; Evan Downs; Rajesh Supra; Alan D Kaye; Omar Viswanath; Ivan Urits Journal: Health Psychol Res Date: 2022-09-23
Authors: Stephen V Faraone; Roberto Gomeni; Joseph T Hull; Gregory D Busse; Zare Melyan; Jonathan Rubin; Azmi Nasser Journal: Paediatr Drugs Date: 2021-09-15 Impact factor: 3.022
Authors: Zhao Wang; Alisa R Kosheleff; Lilian W Adeojo; Oyinkansola Odebo; Toyin Adewole; Peibing Qin; Vladimir Maletic; Stefan Schwabe; Azmi Nasser Journal: Clin Pharmacol Drug Dev Date: 2021-05-04